{"id":"W4295903721","doi":"10.1177/20406207221118429","title":"Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10 9 /L to <100 × 10 9 /L) at baseline: the final analysis of EXPAND","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Genentech; AOP Orphan; Sierra Oncology; CTI Biopharma; Incyte; FibroGen; Gilead Sciences; BeiGene; Sanofi; MorphoSys; Celgene; AstraZeneca; Novartis; Pfizer; Amgen","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Adverse effect; Internal medicine; Clinical endpoint; Anemia; Phases of clinical research; Gastroenterology; Discontinuation; International Prognostic Scoring System; Clinical trial; Bone marrow; Myelodysplastic syndromes","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001412846,0.0005045759,0.0009711421,0.0002672368,0.0002162962,0.0004278398,0.0002914198,0.0003858508,0.001283565],"category_scores_gemma":[0.0009791203,0.0002101386,0.0007279966,0.0002068309,0.0002775638,0.0004866741,0.0003222567,0.0007461471,0.0002463019],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005155226,"about_ca_system_score_gemma":0.0006405453,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003439388,"about_ca_topic_score_gemma":0.001381248,"domain_scores_codex":[0.9995989,0.0001817027,0.00003122379,0.00006818875,0.00006404573,0.00005599135],"domain_scores_gemma":[0.9994349,0.0001562053,0.0001712523,0.00003944802,0.00004334998,0.0001548551],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5271119,0.01004758,0.2407935,0.0006174427,0.002205919,0.0008621794,0.0004290433,0.003162978,0.04242361,0.0003074242,0.004346212,0.1676922],"study_design_scores_gemma":[0.1257861,0.2284953,0.6187454,0.0001323827,0.002445921,0.002160957,0.0001820584,0.00535481,0.01070088,0.000396615,0.005512275,0.00008729869],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980926,0.0006765554,0.0001057911,0.0000746733,0.000004684226,0.000152276,0.0003066148,0.00001219549,0.0005747145],"genre_scores_gemma":[0.9977399,0.000246605,0.0003423809,0.0001406031,0.00002295657,0.0001725341,0.001075462,0.000003096505,0.0002564929],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001412846,"threshold_uncertainty_score":0.007471979,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01325738480847344,"score_gpt":0.2773913357063457,"score_spread":0.2641339508978723,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}